Diligence memo · auto-generated · as of July 3, 2026
Avicanna Inc.
Avicanna Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Avicanna Inc. operates in Pharmaceuticals, based in TORONTO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Avicanna Inc. has raised $9.9M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.5M on 2021-03-04.
Most recent recorded round closed around 2022-08-17.
Valuation (modeled)modeled
Provath models Avicanna Inc. at approximately $24M (range $2.3M–$81M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.75× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era. Within the normal band (75% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 3.9 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 1.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 53% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 31% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.